A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late‐stage lung carcinoma

Abstract

BACKGROUND The authors conducted a pilot clinical trial to explore the vaccination of patients with late‐stage lung carcinoma with dendritic cells (DCs) pulsed with necrotic tumor cells derived from malignant pleural effusion specimens, and to evaluate the antitumor immune response induced by this therapy. METHODS Autologous DCs were generated by culturing adherent mononuclear cells with interleukin‐4 and granulocyte‐macrophage–colony‐stimulating factor for 7 days. Day‐7 DCs were cocultured overnight with autologous necrotic tumor cells derived from pleural effusion specimens to allow internalization of tumor antigens. DCs were then treated with tumor necrosis factor‐alpha for 16 hours. The antigen‐loaded DCs were injected into each patient's inguinal lymph nodes under sonographic guidance. Eight patients with late‐stage nonsmall cell lung carcinoma were treated in this manner. Patients were vaccinated once weekly for 4 weeks and then boosted twice biweekly. RESULTS The authors found that there was no Grade II/III toxicity and autoimmune response in all patients after intranodal injection of the DC vaccine. Minor to moderate increases in T‐cell responses against tumor antigens were observed after DC vaccination in six of eight patients. Five patients had progressive disease. One patient had minor tumor response and two patients had stable disease. The two patients who had longer disease control also had better T‐cell responses. CONCLUSIONS The results indicated that it was feasible to immunize patients with lung carcinoma intranodally with DCs pulsed with necrotic tumor cells enriched from pleural effusion specimens, and this approach may generate T‐cell responses and provide clinical benefit in some patients. Cancer 2005. © 2005 American Cancer Society.

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

“…This has led to interest in targeting vaccines to local lymph node basins to improve the likelihood of activating an effective T cell response (57)(58)(59)(60). The benefit of this approach was demonstrated in a murine model using a lymphocytic choriomeningitis virus peptide vaccine, which induced 10 6 more potent CTL responses when administered by intrasplenic injection compared to subcutaneous vaccination (61).…”

Phenotype of dendritic cells generated in the presence of non-small cell lung cancer antigens - preliminary report.

“…Minor to moderate increases in T-cell responses against tumor antigens were observed after DC vaccination in six of eight patients. One patient had minor tumor response and two patients had a stable disease [15].…”

Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma—A new vaccination strategy

“…Various clinical trials are in progress, designed to test immune-based therapies. 1,[30][31][32] In lung cancer, determinants such as survivin, 33 p185 (HER-2/neu), 34 epidermal growth factor, 35 p53 36 among others 30,32 were identified as potential targets of immune-mediated attack. It is likely that these The same procedure described in (a) was followed except that mAbs for CD41, CD81 or NK1.1 determinants, plus C, were added to the mixed cell cultures 1 hr before the cytotoxicity determinations were performed.…”